Artisan Partners, an investment management company, released its third-quarter 2026 investor letter for the Artisan U.S. Small-Cap Growth Strategy . The letter can be downloaded here. Global equities reached new highs de
Ionis Pharmaceuticals, Inc. (IONS) — Live Session & Technical Brief
Updated Nov 16, 2026 2:36 PM ET · Prev Close $29.06
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-1.70%) in Biotechnology
Ionis Pharmaceuticals, Inc. (IONS) is trading within a tight intraday band at $28.57 (-1.70%, 0.58x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, IONS is trading in line with the S&P 500 (+0.19% alpha). 14-day RSI stands at 23.7, keeping momentum in a oversold regime.
Artisan Partners, an investment management company, released its third-quarter 2026 investor letter for the Artisan U.S. Small-Cap Growth Strategy . The letter can be downloaded here. Global equities reached new highs de
Price ($28.57) trades relative to 20-day SMA ($38.46) and 50-day SMA ($43.07).
Market & Sector Relative Strength
IONS trading in line with the S&P 500 (+0.19% alpha)Recent IONS Catalyst Headlines
Verified WireCarlsbad, Calif., November 12, 2026--Ionis Pharmaceuticals, Inc. Nasdaq IONS today announced new long-term data for Dawnzera donidalorsen , the first and only RNA-targeted medicine for hereditary angioedema HAE , to be p
RNAi adoption accelerates through precision targeting, improved delivery, personalized medicine, agricultural innovation, regulatory approvals and robust funding.Dublin, Nov. 12, 2026 Globe Newswire -- Rna Interference R
IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $28.24 (session support) for directional breakout confirmation.
Technical Regime (IONS)
BEARISH MA TRENDRetail & Crowd Sentiment
Very BullishArtisan Partners exited its investment in Ionis Pharmaceuticals (IONS) following sequential Phase 3 clinical setbacks, according to its Q3 2026 investor letter.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen …
Get Instant IONS Catalyst Alerts
Receive an email alert when IONS triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversIONS Session & Catalyst FAQ
Why is IONS stock trading near flat today?
Ionis Pharmaceuticals, Inc. (IONS) is trading within a tight intraday band at $28.57 (-1.70%, 0.58x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, IONS is trading in line with the S&P 500 (+0.19% alpha). 14-day RSI stands at 23.7, keeping momentum in a oversold regime.
Is IONS stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.58x relative volume (low participation). Our multi-factor model currently rates IONS as HOLD. Review full valuation, quality, and timing signals on the IONS Buy or Sell Decision Brief →
What is IONS's intrinsic value and expected trading range?
At $28.57, IONS's modeled 1-to-3 session range is $27.40 – $29.74, with a key inflection level at $28.24 (session support). Compare current price against multi-year cash flow projections in the IONS Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for IONS?
RSI at 23.7 indicates oversold conditions — watch for mean-reversion support. IONS trades at $28.57 relative to its 20-day SMA ($38.46) and 50-day SMA ($43.07), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.